Long-term benefits and risks of frontline nilotinib vs imatinib for chronic myeloid leukemia in chronic phase: 5-year update of the randomized ENESTnd trial
2016
Long-term benefits and risks of frontline nilotinib vs imatinib for chronic myeloid leukemia in chronic phase: 5-year update of the randomized ENESTnd trial
Keywords:
- Correction
- Source
- Cite
- Save
- Machine Reading By IdeaReader
35
References
463
Citations
NaN
KQI